Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) Invested Capital (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Invested Capital for 16 consecutive years, with $528.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 0.94% to $528.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $528.1 million, a 0.94% decrease, with the full-year FY2024 number at $555.1 million, up 11.47% from a year prior.
  • Invested Capital was $528.1 million for Q3 2025 at Usana Health Sciences, down from $531.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $555.1 million in Q4 2024 to a low of $395.1 million in Q1 2022.
  • A 5-year average of $465.6 million and a median of $462.1 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: grew 26.82% in 2021, then decreased 10.53% in 2022.
  • Usana Health Sciences' Invested Capital stood at $399.1 million in 2021, then increased by 8.87% to $434.5 million in 2022, then increased by 14.62% to $498.0 million in 2023, then rose by 11.47% to $555.1 million in 2024, then dropped by 4.87% to $528.1 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Invested Capital are $528.1 million (Q3 2025), $531.1 million (Q2 2025), and $552.8 million (Q1 2025).